Abstract 2752
Background
The tumor immune microenvironment (TIME) may hold critical information for developing and optimizing immuno-therapeutic approaches, identifying predictive signatures, and selecting the most adequate treatment option for a given patient. Tissue phenomics facilitates the use of the TIME to derive predictive conclusions. The visual information content in histological sections is systematically converted into numerical readouts using artificial intelligence (AI). Resulting quantitative descriptors, phenes, of detected structures are mined to yield local expression profiles; this spatial data aggregation detects categories of local environments, which are correlated to clinical, genomic or other -omics data to identify relevant cohort subpopulations.
Methods
Exploration of this technology is illustrated by various examples on different cohorts of NSCLC patients: A categorization of n = 45 non-IO-treated patients with respect to local immune profiles learned via AI in a hypothesis-free scenario was examined. A deep learning based PD-L1 scoring was compared to 3 pathologist’s scoring on n = 40 durvalumab-treated patients using the cutoff 25% of tumor cells staining positive for PD-L1 at any intensity. The predictive value of a digital signature combining cell densities of PD-L1 and CD8+ was tested on n = 163 durvalumab-treated and n = 199 non-IO-treated samples.
Results
A categorization into biologically interpretable classes learned by AI illustrates the exploratory benefits of tissue phenomics. The scoring algorithm could reproduce survival prediction when compared to pathologist’s visual scoring.The digital signature suggests a predictive value for patient stratification into responders and non-responders for durvalumab, while no prognostic value could be found on the non-IO-treated patients. Kaplan-Meier plots for the 2 latter examples will be presented in the poster.
Conclusions
Tissue phenomics facilitates the quantitative assessment of the tumor geography and may lead to improved tools for biomarker analysis and diagnosis. Analysis on larger and prospective datasets are to be conducted in the future to strengthen the findings.
Clinical trial identification
All of these results have been generated retrospectively from samples unrelated to a trial or related to the durvalumab-trial NCT01693562.
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Boehringer Ingelheim, MedImmune, Definiens AG.
Disclosure
M. Groher: Full / Part-time employment: Definiens AG. J. Zimmermann: Shareholder / Stockholder / Stock options: AstraZeneca; Full / Part-time employment: Definiens AG. H. Musa: Full / Part-time employment: Boehringer Ingelheim. A. Ackermann: Full / Part-time employment: Boehringer Ingelheim. M. Surace: Shareholder / Stockholder / Stock options, Full / Part-time employment: AstraZeneca. J. Rodriguez-Canales: Shareholder / Stockholder / Stock options, Full / Part-time employment: AstraZeneca. M. Rebelatto: Shareholder / Stackeholder / Stock options: AstraZenec LLC; Full / Part-time employment: AstraZeneca LLC. K. Steele: Shareholder / Stockholder / Stock options, Full / Part-time employment: AstraZeneca; Spouse / Financial dependant: Arcellx LLC. A. Kapil: Full / Part-time employment: Definiens AG. N. Brieu: Shareholder / Stockholder / Stock options, Full / Part-time employment: Definiens AG. L. Rognoni: Full / Part-time employment: Definiens AG. F. Segerer: Full / Part-time employment: Definiens AG. A. Spitzmüller: Full / Part-time employment: Definiens AG. T. Tan: Full / Part-time employment: Definiens AG. A. Schäpe: Full / Part-time employment: Definiens AG. G. Schmidt: Full / Part-time employment: Definiens AG; Shareholder / Stockholder / Stock options: AstraZeneca.
Resources from the same session
4489 - A Window of Opportunity Trial of Atorvastatin Targeting p53 Mutant Malignancies
Presenter: Joaquina Baranda
Session: Poster Display session 3
Resources:
Abstract
1945 - Randomized Phase II Study of Trabectedin/Olaparib Compared to Physician’s Choice in Subjects with Previously Treated Advanced or Recurrent Solid Tumors Harboring DNA Repair Deficiencies.
Presenter: Christoph Heilig
Session: Poster Display session 3
Resources:
Abstract
3021 - Homogenisation of Leftover Surgical Tissue across multiple cancer types: a Feasibility Study (HoLST-F)
Presenter: Lavinia Spain
Session: Poster Display session 3
Resources:
Abstract
2882 - Safety, efficacy, and immune effects of intratumoral tilsotolimod in patients with refractory solid tumors: updated results from ILLUMINATE-101
Presenter: Hani Babiker
Session: Poster Display session 3
Resources:
Abstract
1950 - Phase 1 Dose Escalation of MSC-1, a humanized anti-LIF monoclonal antibody, in patients (pts) with advanced solid tumors: Updated results
Presenter: Erkut Borazanci
Session: Poster Display session 3
Resources:
Abstract
2391 - A phase 1 study of Sym021, an anti-PD-1 antibody (Ab), alone and in combination with Sym022 (anti-LAG-3) or Sym023 (anti-TIM-3)
Presenter: Anna Spreafico
Session: Poster Display session 3
Resources:
Abstract
5692 - FPA150 (B7-H4 antibody) Phase 1 Update in Advanced Solid Tumors: Monotherapy and in Combination with Pembrolizumab
Presenter: Zev Wainberg
Session: Poster Display session 3
Resources:
Abstract
2416 - MG1124, a novel CEACAM1-targeted monoclonal antibody, has therapeutic potential as a combination partner of PD-1 inhibitors in NSCLC patients
Presenter: Eun Hee Lee
Session: Poster Display session 3
Resources:
Abstract
2661 - Tumor stroma targeting and modulation by OMTX705 ADC, a novel and potent immunotherapeutic treatment of solid tumors.
Presenter: Myriam Fabre
Session: Poster Display session 3
Resources:
Abstract
3681 - Durvalumab + monalizumab, mFOLFOX6, and bevacizumab in patients (pts) with metastatic microsatellite-stable colorectal cancer (MSS-CRC)
Presenter: May Cho
Session: Poster Display session 3
Resources:
Abstract